Ignite Creation Date:
2024-05-05 @ 10:45 PM
Last Modification Date:
2024-10-26 @ 10:23 AM
Study NCT ID:
NCT01177059
Status:
COMPLETED
Last Update Posted:
2018-12-12
First Post:
2010-08-05
Brief Title:
Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 HIV-1 Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial
Sponsor:
Janssen-Cilag Pty Ltd
Organization:
Janssen-Cilag Pty Ltd
Study Overview
Official Title:
A Long Term Follow-up Protocol to Evaluate the Safety and Survival of Autologous CD34 Hematopoietic Progenitor Cells Transduced With an Anti-HIV-1 Ribozyme OZ1 in Patients With HIV-1 Infection
Status:
COMPLETED
Status Verified Date:
2018-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this Observational Study is long term follow-up of the Human Immunodeficiency Virus -1 HIV-1 infected patients who have received a gene therapy product anti-HIV-1 Ribozyme OZ1 as part of an earlier phase 2 trial Patients are seen twice yearly until 5 years from initial infusion of study drug has elapsed and then yearly until withdrawal or study completion The study will monitor for and record any ill effects from the gene therapy product to provide long term safety information
Detailed Description:
During an earlier phase 2 base trial study NCT00074997 HIV-1 infected patients received a gene therapy product anti-HIV-1 Ribozyme OZ1 Gene therapy is an investigational treatment where genes are inserted into an individuals cells and tissues to treat a disease The gene therapy OZ1 is thought to have anti-HIV-1 actions This is an Observational Study to provide long term follow-up of those HIV-1 infected patients who received the gene therapy product anti-HIV-1 Ribozyme OZ1 as part of the earlier study Patients are seen twice yearly until 5 years from initial infusion of study drug has elapsed and then yearly until withdrawal or study completion The study will monitor for and record any ill effects from the gene therapy product to provide long term safety information Observational study - no investigational drug administered
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| OZ1-HV1-202 | OTHER | Janssen-Cilag Pty Ltd Australia | None |